On July 15, WuXi XDC rose 3.5% in regular trading, trading at 60.65 HKD/share, with turnover of approximately 36.09 million HKD. The gain was driven by continued strength across the CXO sector and a wave of bullish research coverage from major international investment banks.

On the news front, multiple brokerages have recently issued positive ratings on the company. CLSA raised its target price to 82.6 HKD while maintaining an Outperform rating, citing strong early-to-mid-stage ADC R&D investment, a biotech funding recovery in H1, and global ADC outsourcing market share gains. Daiwa initiated coverage with a Buy rating and a 78 HKD target, naming WuXi XDC a top pick in China's CXO industry, highlighting its 24% market share in ADC CDMO services. BOCOM International also assigned an Outperform rating with an 80 HKD target. Sector peers rallied in tandem, with Pharmaron up 5.68%, WuXi AppTec up 3.54%, WuXi Biologics up 3.35%, and Joinn Laboratories up 12.61%. Fundamentally, the company's backlog stands at approximately USD 1.489 billion, up 50.3% year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)